Organon, a global healthcare company focused on women’s health, has finalized its acquisition of Dermavant Sciences Ltd. from Roivant. This strategic move bolsters Organon’s dermatology offerings with the addition of VTAMA® (tapinarof) cream, 1%, a novel topical treatment for plaque psoriasis in adults.
VTAMA, a non-biologic, non-steroidal therapy, stands out for its favorable safety profile, lacking the warnings, precautions, and usage limitations often associated with other treatments. The acquisition reflects Organon’s commitment to providing innovative solutions for chronic skin conditions.
Currently, the U.S. Food and Drug Administration (FDA) is evaluating a supplemental New Drug Application (sNDA) for VTAMA cream as a potential treatment for atopic dermatitis (commonly known as eczema) in adults and children aged two and above. A decision from the FDA is anticipated in the fourth quarter of 2024.
Both plaque psoriasis and atopic dermatitis are prevalent inflammatory skin diseases, impacting a significant population globally and carrying a substantial burden, particularly for women. Integrating Dermavant’s expertise into Organon’s U.S. operations signifies a pivotal advancement in dermatological care. Organon aims to leverage its global reach and commercial capabilities to maximize the availability of VTAMA to patients worldwide. This acquisition exemplifies a collaborative approach to address unmet patient needs and advance dermatological solutions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
